PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Bronchitis

Drugs in development · updated 30 October 2026

Bronchitis: drugs in development

As of 30 October 2026 there are 3 active clinical trials (recruiting or ongoing, phases I–III) on 6 drugs for bronchitis. 6 are experimental, that is not yet approved in the United States.

3Active trials
6Experimental drugs
4Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
AG2001III1NCT07198347
AG20011III1NCT07198347
AG20012III1NCT07198347
RaphaminIII1NCT07650227
EXPD-101II1NCT07684820
FXS7553II1NCT07684820

Sorted by most advanced phase and number of active trials.

All 6 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Specific forms

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D001991 “Bronchitis”.

ItalianoFrançaisDeutsch